View more job listings or post a job
Jazz Pharmaceuticals Senior Manager, Clinical Pharmacology
Nektar Therapeutics Research Associate III
Nektar Therapeutics Sr. Scientist, Bioanalytical
Genentech, Inc. Associate Scientist/Scientist, Drug Metabolism and Pharmacokinetics
Jubilant Discovery Services Senior Manager Business Development
Aimmune Therapeutics The Associate Director, Quality Control will be a key member of the analytical team and he/she will support activities associated with quality control activities of Aimmune’s APIs and drug products conducted at CTL/CMO.  
Precision for Medicine Senior Manager, Quality Assurance
Denali Therapeutics Bioanalytical Research Scientist, DMPK (SM/Biomarker)
Arena Pharmaceuticals The Principal Scientist will report to the Head of Analytical Sciences and will serve as the analytical lead in cross-functional product development tea
Genentech Associate Scientist/Scientist, Process Analytical Technology, Small Molecule Analytical Chemistry  
Post a job


No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond

Speakers: Carolyn Bertozzi (Stanford), Michelle Arkin (UCSF), Adrian Gill (Revolution Medicines), Michael Keiser (UCSF), Mark Smith (Stanford), Maureen Hillenmeyer (Hexagon Bio), Ian Seiple (UCSF), Daniel Erlanson (Carmot Therapeutics), Chaitan Khosla (Stanford)
Organizers: Toni Kline, PhD
Date: 2020-05-22
Time: 8:30-17:00 Pacific Time
Registration fee (USD): Regular: $195; Academic: $125; Students & Unemployed: $35
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date: (2)Applied StemCell; Emerson Collective
Registration deadline:2020-05-20  (it will close sooner if the seating cap is reached)

About the Topic

Proteins function in a physiological environment of access barriers, regulators, facilitators, and partners. In many therapeutic ecologies, single drug-single target does not apply. To target these dynamics new modalities of both drug and drug discovery are being explored. This Symposium will highlight some emerging ones.  

Part A. Beyond Target Binding

Classic drug-target interactions are typically viewed as a non-covalent association of the small molecule drug with a single protein receptor, active, or allosteric site; this binding blocks protein reaction with the native agonist or substrate, and the offending signal is quenched.  The limitations of this vision become clear when in vitro results do not translate into in vivo efficacy.

Engineering the small molecule to accommodate and exploit the complexities of ADME-- and systems biology-- is now being accomplished in a number of creative ways: Much as we once naively talked about “junk DNA” and “undruggable” targets, we now have the insight and tools to understand the therapeutic potential embedded in complex biological systems.

Part B. Towards the rest of that chemical space.

Library (high-throughput or more modest) screening, and modifications of known drugs have been engines of the discovery process for a century. Along with combinatorial chemistry and computer assisted drug discovery (CADD), these methods have brought thousands of molecules to the clinic. But a certain ”drug-like” sameness often appears across therapeutic groups.  Perhaps for good reason (ADME, PK properties are optimized according to established conventions), but this sameness is at the expense of exploring truly novel chemical space. Happily, the discovery process is not static, and technologies are emerging to identify less obvious and less familiar-looking molecules.  In the oncology and antibiotic spaces, drugs arising from these methods might encounter less resistance.


Topics & Speakers:

  • LYTACs/PROTACsCarolyn Bertozzi, PhD, Professor of Chemical & Systems Biology and Radiology, Stanford University
  • Protein-protein interactionsMichelle Arkin, PhD, Co-director, Small Molecule Discovery Center (SMDC), Professor, Pharmaceutical Chemistry, UCSF    
  • Allosteric inhibitorsAdrian Gill, PhD, VP Medicinal Chemistry and CMC, REVOLUTION Medicines
  • Systems pharmacology and forward polypharmacologyMichael Keiser, PhD, Professor, Institute for Neurodegenerative Diseases, UCSF
  • Discovery at the academia/biotech borderline: Mark Smith, PhD, Head, ChEM-H Medicinal Chemistry Knowledge Center, Stanford University
  • AI meets fermentation: Maureen Hillenmeyer, PhD, CEO, Hexagon Bio      
  • Access to complex natural products: Ian Seiple, PhD, Professor in Residence, Cardiovascular Research Institute, UCSF
  • Fragment based drug discoveryDaniel Erlanson, PhD, Co-Founder and VP of Chemistry, Carmot Therapeutics
  • Directed evolution: Chaitan Khosla, PhD, Professor of Chemical Engineering and Chemistry, Stanford University

2019-11-12, Antibody Drug Discovery and Development: Hit Generation, Engineering, Cell-line Development, IND enabling studies, and Biosimilars
2019-12-10, In Vitro Diagnostics (IVD), Companion Diagnostics (CDx) and Precision Medicine
2020-01-10, All about half-life: which one should I use? (tentative title)
2020-01-21, Considerations for Successful Clinical Development: Fundamentals and Best Practices for Clinical Trial Design, Biostatistics, and Data Management
2020-02-11, Development of Drug/Device Combinations
2020-02-24, MS Courses by Dr. Jack Henion: Advanced LC-MS/MS (Day1) & Interpretation of MS/MS CID Spectra (Day2)
2020-03-16, Clinical Trials Essentials: An Intensive One-Week Course (register for the full week or half day sessions)
2020-04-10, Biopolymer-based conjugation of therapeutic proteins and antibodies for improving drug properties (tentative title)
2020-05-12, Regulated Large Molecule Bioanalysis: Fundamentals, the New FDA Guidance and Beyond
2020-06-23, Advances in Immuno-Oncology (A Joint Symposium by PBSS and BioScience Forum)
┬ęPharmaceutical & BioScience Society, International; Last Modified: 10/20/2019; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Origin Bioanalytical Laboratory Sacramento-based CRO for bioanalytical method development, validation, and consulting of LC-MS/MS analysis, specializing in ocular matrices
XCELERATE at Biotech Week Boston Driving the Future of the Life Science Industry. Sept. 11 at BCEC. Learn more.
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS & GC-MS/MS bioanalytical quantitation services of small & large molecules in any matrix. Discovery through phase IV.
BIOTECH WEEK BOSTON - Sept. 9-12 Access over 5,000 of the most innovative scientific minds & business leaders in Boston and around the world. Learn More.
UC Davis UC Davis LC/MS Confirmation Supervisor (Lab Rsch Supv 2) Apply Online: UC Davis is an AA/EOE
Adesis Inc. Adesis provides expertise in custom synthesis, process dev, R&D, and specialty mfg. to pharma, chemical, biomaterials, and catalysts companies
Submit a Text Ad